только для медицинских специалистов
Консультант врача. Электронная медицинская библиотека

Консультант врача

Электронная медицинская библиотека

Доступ к библиотеке Версия для слабовидящих
Раздел 5 / 11
Страница 1 / 1

Список литературы

  1. Давыдов М.И. Энциклопедия клинической онкологии. – М.: ООО «РЛС-2004», 2004.
  2. Каприн А.Д., Старинский В.В. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). – М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. – С.11, 15, 16.
  3. CANCER TODAY. URL: https://gco.iarc.fr/today/online-analysis-ta-ble? v=2018&mode=cancer&mode_population=continents&population=900&populations=908_643&key
  4. Snyderman N.L., Johnson J.T. Salivary gland tumors. Diagnostic characteristics of the common types. Postgrad Med. 1987 Oct. 82(5):105–8, 110–2.
  5. Calearo C, Pastore A, Storchi OF, Polli G. Parotid gland carcinoma: analysis of prognos-tic factors. Ann Otol Rhinol Laryngol 1998; 107:969–973.
  6. Bobati S.S., Patil B.V., Dombale V.D. Histopathological study of salivary gland tumors J Oral Maxillofac Pathol. 2017 Jan-Apr; 21(1): 46–50.
  7. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Salivary Gland Tumors. Version 3.2019.
  8. Hocwald, E., Korkmaz, H., Yoo, G. H., Adsay, V., Shibuya, T. Y., Abrams, J., & Jacobs, J. R. (2001). Prognostic Factors in Major Salivary Gland Cancer. The Laryngoscop.
  9. Stodulski, D., Mikaszewski, B., & Stankiewicz, C. (2011). Are all prognostic factors in parotid gland carcinoma well recognized? European Archives of Oto-Rhino-Laryngology, 269(3), 1019– 1025.
  10. Suzuki M., Ichimiya I., Matsushita F., et al. Histological features and prognosis of pa-tients with mucoepidermoid carcinoma of the parotid gland. J Laryngol Otol. 1998 Oct. 112(10):944–7.
  11. Ghosh-Laskar S., Murthy V., Wadasadawala T., Agarwal J., Budrukkar A., Patil N., et al. Mucoepidermoid carcinoma of the parotid gland: Factors affecting outcome. Head Neck. 2011 Apr. 33(4):497–503.
  12. De Bondt R. B. J. et al. Detection of lymph node metastases in head and neck cancer: a meta- analysis comparing US, USgFNAC, CT and MR imaging //European journal of ra-diology. – 2007. – Т. 64. – №. 2. – С. 266-272.
  13. Rice D.H., Becker T. Magnetic resonance imaging of the salivary glands. A comparison with computed tomographic scanning. Arch Otolaryngol Head Neck Surg. 1987 Jan. 113(1):78–80.
  14. Ruhlmann V., Poeppel T.D., Veit J. et al. Diagnostic accuracy of 18F–FDG PET/CT and MR imaging in patients with adenoid cystic carcinoma. BMC Cancer. 2017; 17: 887.
  15. Liu C. C. et al. Sensitivity, specificity, and posttest probability of parotid fine-needle as- piration: a systematic review and meta-analysis //Otolaryngology--Head and Neck Sur-gery. – 2016. – Т. 154. – №. 1. – С. 9-23.
  16. Wang X., Luo Y., Li M. et al., Management of salivary gland carcinomas - a review. Oncotarget, 2017, Vol. 8, (No. 3), pp: 3946-3956.
  17. Johns M.E. Parotid cancer: a rational basis for treatment. Head Neck Surg. 1980 NovDec. 3(2):132–41.
  18. Chen AM, Garcia J, Granchi PJ. Late recurrence from salivary gland cancer: when does “cure” mean cure? Cancer. 2008;112(2):340-4.
  19. Sood, S., McGurk, M., & Vaz, F. (2016). Management of Salivary Gland Tumours: Unit-ed Kingdom National Multidisciplinary Guidelines. The Journal of Laryngology & Otol-ogy, 130(S2), S142–S149.
  20. Boon E, van Boxtel W, Buter J, et al. Androgen deprivation therapy for androgen recep-tor- positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands. Head Neck 2018;40:605-613.
  21. Haddad, R., Colevas, A. D., Krane, J. F., Cooper, D., Glisson, B., Amrein, P. C., … Pos-ner, M. (2003). Herceptin in patients with advanced or metastatic salivary gland carcino-mas. A phase II study. Oral Oncology, 39(7), 724–727.
  22. Perissinotti A. J. et al. The role of trastuzumab in the management of salivary ductal car- cinomas //Anticancer research. – 2013. – Т. 33. – №. 6. – С. 2587-2591.
  23. Terhaard C. H. J. et al. The role of radiotherapy in the treatment of malignant salivary gland tumors //International Journal of Radiation Oncology* Biology* Physics. – 2005. – Т. 61. – №. 1. – С. 103-111.
  24. Cheraghlou S, Kuo P, Mehra S et al. Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database. Head Neck. 2018 Jul;40(7):1343-1355.
  25. Adelstein, D. J., Li, Y., Adams, G. L., Wagner, H., Kish, J. A., Ensley, J. F., … Foras-tiere, A. A. (2003). An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable S.
  26. Airoldi M, Fornari G, Pedani F, et al. Paclitaxel and carboplatin for recurrent sali-vary gland malignancies. Anticancer Res 2000; 20: 3781–83.
  27. Dick Haan, L. D., De Mulder, P. H. M., Vermorken, J. B., Schornagel, J. H., Vermey, A., & Verweij, J. (1992). Cisplatin-based chemotherapy in advanced ad-enoid cystic carcinoma of the head and neck. Head & Neck, 14(4), 273–277.
  28. Болтина Л.В., Владимирова Ю.В., Деньгина Н.В. и соавт. Практические рекомен-дации по лекарственному лечению злокачественных опухолей головы и шеи. Зло-качественные опухоли: Практические рекомендации по лекарственному лечению злокачественных опухолей (RUSS.
  29. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Principles of Surgery. Version 2.2018.
  30. Domenick N.A., Johnson J.T. Parotid tumor size predicts proximity to the facial nerve. Laryngoscope. 2011 Nov. 121(11):2366–70.
  31. Ord, R. A., & Ghazali, N. (2017). Margin Analysis. Oral and Maxillofacial Surgery Clin-ics of North America, 29(3), 315–324.
  32. Silver J.A., Baima J. Cancer prehabilitation: anopportunity to decrease treatment related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2103; 92: 715–727.
  33. Buffart L.M., Sweegers M.G., May A.M., et al. Targeting Exercise Interventions to Pa-tients With Cancer in Need: An Individual Patient Data Meta-Analysis. J Natl Cancer Inst. 2018 Nov 1;110(11):1190–1200. DOI: 10.1093/jnci/djy161.
  34. Paskett ED, Dean JA, Oliveri JM, Harrop JP. Cancer-related lymphedema risk fac-tors, diagnosis treatment and impact: a review. J Clinl Oncol. 2012;30(30):3726-3733.
  35. Clarke P., Radford K., Coffey M., Stewart M. Speech and swallow rehabilitation in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016 May;130(S2):S176–S180.
  36. Colevas A.D., Yom S.S., Pfister D.G., et al. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. J Natl Compr Canc Netw. 2018 May;16(5):479–490. DOI: 10.6004/jnccn.2018.0026.
  37. Практические рекомендации по нутритивной поддержке у онкологических боль-ных / Снеговой А.В., Бесова Н.С., Веселов А.В., Кравцов С.А., Ларионова В.Б., Сельчук В.Ю. и соавт. Злокачественные опухоли. 2016. № 4. Спецвыпуск 2. С. 434-450.
  38. Arends J., Bachmann P., Baracos V., et al. ESPEN guidelines on nutrition in cancer pa-tients. Clinical Nutrition. 2017;36: Pp. 11–48.
  39. Thompson KL, Elliott L, Fuchs-Tarlovsky V, et al. Oncology evidence-based nutrition practice guideline for.
  40. Kim W.S., Lee H.S., Park Y.M., et al. Surgical Outcomes of Parotid Cancer: A 10-Year Experience. Otolaryngol Head Neck Surg. 2012 Aug. 147(2 suppl):Pp. 180–181.
  41. Hubera G.F., Dort J.C. Reducing morbidity and complications after major head and neck cancer surgery: the (future) role of enhanced recovery after surgery protocols. Curr Opin Otolaryngol Head Neck Surg 2018.
  42. Coyle, M. J., Main, B., Hughes, C., et al. (2016). Enhanced recovery after surgery (ERAS) for head and neck oncology patients. Clinical Otolaryngology, 41(2), 118–126.
  43. Midgley A.W., Lowe D., Levy A.R., Mepani V., Rogers S.N. Exercise program design considerations for head and neck cancer survivors. Eur Arch Otorhinolaryngol. 2018;275(1):169– 179.
  44. Guru K., Manoor U.K., Supe S.S. A comprehensive review of head and neck cancer re- habilitation: physical therapy perspectives. Indian J Palliat Care. 2012 May-Aug;18(2):87–97.
  45. Goel V., Nemade H., Raju K.V.V.N., Rao C.S. (2017) Physiotherapy and Head and Neck Cancers. J Nov Physiother 7:337.
  46. Logemann J.A., Pauloski B.R., et al. Speech and Swallowing Rehabilitation for Head and Neck Cancer Patients. ONCOLOGY 11(5):651-659, 1997.
  47. Wall L.R., Ward E.C., Cartmill B., Hill A.J. Physiological changes to the swallowing mechanism following (chemo)radiotherapy for head and neck cancer: a systematic review. Dysphagia 2013;28(4):481–93.
  48. Govender R., Smith C.H., Taylor S.A. et al. Swallowing interventions for the treatment of dysphagia after head and neck cancer: a systematic review of behavioural strategies used to pro- mote patient adherence to swallowing exercises. BMC Cancer 2017;17(1).
  49. Zagari P.R.P.P., Paulon R.M.C., Farias L.P. (2018) Rehabilitation After Tracheostomy. In: de Farias T. (eds) Tracheostomy. Springer, Cham.
  50. Starmer, H. M., Ayoub, N., Byward, C., Kizner, J., Le, Q., Hara, W., & Holsinger, F. C. (2017). The impact of developing a speech and swallow rehab program: Improving patient satis-faction and multidisciplinary care. The Laryngoscope, 127(11), 2578–2581.
  51. Mina D.S., Alibhai S.M.H., Matthew A.G., Guglietti C.L., Steele J., Trachtenberg J., Ritvo P.G. Exercise in clinical cancer care: a call to action and program development de-scription. Curr Oncol, 2012;19(3), pp. e136–144.
  52. Segal R., Zwaal C., Green E., Tomasone J.R., Loblaw A., Petrella T. Exercise for people with cancer: a clinical practice guideline. Curr Oncol. 2017;24(1):40-46.
  53. Pauli N., Svensson U., Karlsson T., Finizia C. Exercise intervention for the treatment of trismus in head and neck cancer − a prospective two-year follow-up study. Acta Oncol. 2016 Jun;55(6):686-92.
  54. Smith B.G., Lewin J.S. Lymphedema management in head and neck cancer. Curr Opin Otolaryngol Head Neck Surg 2010;18(3):153–8.
  55. Vignes S. Lymphedema: from diagnosis to treatment. Rev Med Interne 2017;38(2):97–105.
  56. Doke K.N., Bowman L., Shnayder Y., et al. Quantitative clinical outcomes of therapy for head and neck lymphedema. Adv Radiat Oncol. 2018 Apr 27;3(3):366–371.
  57. Tacani P.M., Franceschini J.P., Tacani R.E., et al. Retrospective study of the physical therapy modalities applied in head and neck lymphedema treatment. Head Neck. 2016 Feb;38(2):301–8.
  58. Wigg J. Use and response to treatment using low level laser therapy. J Lymphoedema 2009;4(2):73–6. Lee N., Wigg J., Carroll J. D. The use of low level light therapy in the treatment of head and neck oedema. J Lymphoedema 2013;8(1):35–42.
  59. Ткаченко Г.А. Клинико-психологическое исследование качества жизни больных, страда-ющих злокачественными новообразованиями челюстно-лицевой области. Вестник психо-терапии. 2012. № 44 (49). С. 57−63.
  60. Zhao, S. G., Alexander, N. B., Djuric, Z., Zhou, J., Tao, Y., Schipper, M., … Jolly, S. (2015). Maintaining physical activity during head and neck cancer treatment: Results of a pilot controlled trial. Head & Neck, 38(S1), E1086–E1096.
  61. Segal R., Zwaal C., Green E. et al. Exercise for people with cancer: a systematic review. Curr Oncol. 2017 Aug; 24(4): e290–e315.
  62. Samuel S.R., Maiya G.A., Fernandes D.J., Guddattu V., Saxena P.U.P., Kurian J.R., Lin P.-J., Mustian K.M. Effectiveness of exercise-based rehabilitation on functional capacity and quality of life in head and neck cancer patients receiving chemoradiotherap.
  63. Mustian K.M., Alfano C.M., Heckler C., et al: Comparison of pharmaceutical, psycholog-ical, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017;3:961–968.
  64. Lee J.M., Look R.M., Turner C. et al. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. J Clin Oncol 2012;30(15):90-91.
  65. Rick O., von Hehn U., Mikus E., Dertinge H., Geiger G. Magnetic field therapy in pa-tients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. Bioelectromagnetics, 2016:38(2), 85–94.
  66. Gewandter J. S. et al. Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study //Supportive Care in Cancer. – 2019. – Т. 27. – №. 5. – С. 1765-1774.
  67. Oberoi S., Zamperlini-Netto G., Beyene J., Treister N.S., Sung L. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. Send to PLoS One. 2014 Sep 8;9(9):e107418.
  68. Anschau, F., Webster, J., Capra, M. E. Z., de Azeredo da Silva, A. L. F., & Stein, A. T. (2019). Efficacy of low-level laser for treatment of cancer oral mucositis: a systematic re-view and meta- analysis. Lasers in Medical Science. doi:10.1007/s10103-019-.
  69. Bensadoun R.J., Nair R.G. Low-level laser therapy in the management of mucositis and dermatitis induced by cancer therapy. Photomed Laser Surg. 2015;33(10):487–491.
  70. Renehan A1, Gleave EN, Hancock BD et al. Long-term follow-up of over 1000 patients. Br J Surg. 1996 Dec;83(12):1750-4.
  71. Решетов И.В., Славнова Е.Н., Волченко Н.Н. и др. Опухоли головы и шеи. Технологии лечения, реконструкции, реабилитации. Монография. − Москва, 2016. С. 514.
  72. Walker M.P., Wichman B., Cheng A.L., Coster J., Williams K.B. Impact of radiotherapy dose on dentition breakdown in head and neck cancer patients. Pract Radiat Oncol 2011;1:142–148.
  73. Little M., Schipper M., Feng F.Y., et al. Reducing xerostomia after chemo-IMRT for head- and-neck cancer: beyond sparing the parotid glands. Int J Radiat Oncol Biol Phys 2012;83:1007– 1014.
  74. Studer G., Glanzmann C., Studer S.P., et al. Risk-adapted dental care prior to intensity- modulated radiotherapy (IMRT). Schweiz Monatsschr Zahnmed 2011;121:216–229.
  75. Murdoch-Kinch C.A., Zwetchkenbaum S. Dental management of the head and neck can-cer patient treated with radiation therapy. J Mich Dent Assoc 2011;93:28–37.
  76. Epstein J.B., Thariat J., Bensadoun R.J., et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin 2012;62:400–422.
  77. Lee I.J., Koom W.S., Lee CGet al. Risk factors and dose-effect relationship for mandibu-lar osteoradionecrosis in oral and oropharyngeal cancer patients. Int J Radiat Oncol Biol Phys 2009;75:1084–1091.
  78. Sim, C. P. C., Walker, G. D., Manton, D. J., Soong, Y.-L., Wee, J. T. S., Adams, G. G., & Reynolds, E. C. (2018). Anticariogenic efficacy of a saliva biomimetic in head-and-neck cancer patients undergoing radiotherapy. Australian Dental Jour-nal.doi:10.11.
  79. Al-Joburi W., Clark C., Fisher R. A comparison of the effectiveness of two systems for the prevention of radiation caries //Clinical preventive dentistry. – 1991. – Т. 13. – №. 5. – С. 15-19.

Для продолжения работы требуется вход / регистрация